Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysis.
Humans
Cost-Benefit Analysis
Peritoneal Neoplasms
/ secondary
Hyperthermic Intraperitoneal Chemotherapy
Cytoreduction Surgical Procedures
/ economics
Technology Assessment, Biomedical
Randomized Controlled Trials as Topic
Female
Quality-Adjusted Life Years
Ovarian Neoplasms
/ pathology
Hyperthermia, Induced
/ economics
Cost-Effectiveness Analysis
COST-EFFECTIVENESS ANALYSIS
COST-UTILITY ANALYSIS
EVIDENCE-BASED MEDICINE
HYPERTHERMIC INTRAOPERATIVE PERITONEAL CHEMOTHERAPY
META-ANALYSIS
PERITONEAL METASTASES
PROBABILISTIC SENSITIVITY ANALYSIS
SYSTEMATIC REVIEW
VALUE OF INFORMATION ANALYSIS
Journal
Health technology assessment (Winchester, England)
ISSN: 2046-4924
Titre abrégé: Health Technol Assess
Pays: England
ID NLM: 9706284
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
10
9
2024
Statut:
ppublish
Résumé
We compared the relative benefits, harms and cost-effectiveness of hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery ± systemic chemotherapy versus cytoreductive surgery ± systemic chemotherapy or systemic chemotherapy alone in people with peritoneal metastases from colorectal, gastric or ovarian cancers by a systematic review, meta-analysis and model-based cost-utility analysis. We searched MEDLINE, EMBASE, Cochrane Library and the Science Citation Index, ClinicalTrials.gov and WHO ICTRP trial registers until 14 April 2022. We included only randomised controlled trials addressing the research objectives. We used the Cochrane risk of bias tool version 2 to assess the risk of bias in randomised controlled trials. We used the random-effects model for data synthesis when applicable. For the cost-effectiveness analysis, we performed a model-based cost-utility analysis using methods recommended by The National Institute for Health and Care Excellence. The systematic review included a total of eight randomised controlled trials (seven randomised controlled trials, 955 participants included in the quantitative analysis). All comparisons other than those for stage III or greater epithelial ovarian cancer contained only one trial, indicating the paucity of randomised controlled trials that provided data. For colorectal cancer, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably results in little to no difference in all-cause mortality (60.6% vs. 60.6%; hazard ratio 1.00, 95% confidence interval 0.63 to 1.58) and may increase the serious adverse event proportions compared to cytoreductive surgery ± systemic chemotherapy (25.6% vs. 15.2%; risk ratio 1.69, 95% confidence interval 1.03 to 2.77). Hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably decreases all-cause mortality compared to fluorouracil-based systemic chemotherapy alone (40.8% vs. 60.8%; hazard ratio 0.55, 95% confidence interval 0.32 to 0.95). For gastric cancer, there is high uncertainty about the effects of hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy versus cytoreductive surgery + systemic chemotherapy or systemic chemotherapy alone on all-cause mortality. For stage III or greater epithelial ovarian cancer undergoing interval cytoreductive surgery, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably decreases all-cause mortality compared to cytoreductive surgery + systemic chemotherapy (46.3% vs. 57.4%; hazard ratio 0.73, 95% confidence interval 0.57 to 0.93). Hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy may not be cost-effective versus cytoreductive surgery + systemic chemotherapy for colorectal cancer but may be cost-effective for the remaining comparisons. We were unable to obtain individual participant data as planned. The limited number of randomised controlled trials for each comparison and the paucity of data on health-related quality of life mean that the recommendations may change as new evidence (from trials with a low risk of bias) emerges. In people with peritoneal metastases from colorectal cancer with limited peritoneal metastases and who are likely to withstand major surgery, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy should not be used in routine clinical practice ( More randomised controlled trials are necessary. This study is registered as PROSPERO CRD42019130504. This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/135/02) and is published in full in Cancers of the bowel, ovary or stomach can spread to the lining of the abdomen (‘peritoneal metastases’). Chemotherapy (the use of drugs that aim to kill cancer cells) given by injection or tablets (‘systemic chemotherapy’) is one of the main treatment options. There is uncertainty about whether adding cytoreductive surgery (cytoreductive surgery; an operation to remove the cancer) and ‘hyperthermic intraoperative peritoneal chemotherapy’ (warm chemotherapy delivered into the lining of the abdomen during cytoreductive surgery) are beneficial. We reviewed all the information from medical literature published until 14 April 2022, to answer the above uncertainty. We found the following from eight trials, including about 1000 participants. In people with peritoneal metastases from bowel cancer, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably does not provide any benefits and increases harm compared to cytoreductive surgery + systemic chemotherapy, while cytoreductive surgery + systemic chemotherapy appears to increase survival compared to systemic chemotherapy alone. There is uncertainty about the best treatment for people with peritoneal metastases from stomach cancer. In women with peritoneal metastases from ovarian cancer who require systemic chemotherapy before cytoreductive surgery to shrink the cancer to allow surgery (‘advanced ovarian cancer’), hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably increases survival compared to cytoreductive surgery + systemic chemotherapy. In people who can withstand a major operation and in whom cancer can be removed, cytoreductive surgery + systemic chemotherapy should be offered to people with peritoneal metastases from bowel cancer, while hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy should be offered to women with peritoneal metastases from ‘advanced ovarian cancer’. Uncertainty in treatment continues for gastric cancer. This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/135/02) and is published in full in
Sections du résumé
Background
UNASSIGNED
We compared the relative benefits, harms and cost-effectiveness of hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery ± systemic chemotherapy versus cytoreductive surgery ± systemic chemotherapy or systemic chemotherapy alone in people with peritoneal metastases from colorectal, gastric or ovarian cancers by a systematic review, meta-analysis and model-based cost-utility analysis.
Methods
UNASSIGNED
We searched MEDLINE, EMBASE, Cochrane Library and the Science Citation Index, ClinicalTrials.gov and WHO ICTRP trial registers until 14 April 2022. We included only randomised controlled trials addressing the research objectives. We used the Cochrane risk of bias tool version 2 to assess the risk of bias in randomised controlled trials. We used the random-effects model for data synthesis when applicable. For the cost-effectiveness analysis, we performed a model-based cost-utility analysis using methods recommended by The National Institute for Health and Care Excellence.
Results
UNASSIGNED
The systematic review included a total of eight randomised controlled trials (seven randomised controlled trials, 955 participants included in the quantitative analysis). All comparisons other than those for stage III or greater epithelial ovarian cancer contained only one trial, indicating the paucity of randomised controlled trials that provided data. For colorectal cancer, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably results in little to no difference in all-cause mortality (60.6% vs. 60.6%; hazard ratio 1.00, 95% confidence interval 0.63 to 1.58) and may increase the serious adverse event proportions compared to cytoreductive surgery ± systemic chemotherapy (25.6% vs. 15.2%; risk ratio 1.69, 95% confidence interval 1.03 to 2.77). Hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably decreases all-cause mortality compared to fluorouracil-based systemic chemotherapy alone (40.8% vs. 60.8%; hazard ratio 0.55, 95% confidence interval 0.32 to 0.95). For gastric cancer, there is high uncertainty about the effects of hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy versus cytoreductive surgery + systemic chemotherapy or systemic chemotherapy alone on all-cause mortality. For stage III or greater epithelial ovarian cancer undergoing interval cytoreductive surgery, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably decreases all-cause mortality compared to cytoreductive surgery + systemic chemotherapy (46.3% vs. 57.4%; hazard ratio 0.73, 95% confidence interval 0.57 to 0.93). Hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy may not be cost-effective versus cytoreductive surgery + systemic chemotherapy for colorectal cancer but may be cost-effective for the remaining comparisons.
Limitations
UNASSIGNED
We were unable to obtain individual participant data as planned. The limited number of randomised controlled trials for each comparison and the paucity of data on health-related quality of life mean that the recommendations may change as new evidence (from trials with a low risk of bias) emerges.
Conclusions
UNASSIGNED
In people with peritoneal metastases from colorectal cancer with limited peritoneal metastases and who are likely to withstand major surgery, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy should not be used in routine clinical practice (
Future work
UNASSIGNED
More randomised controlled trials are necessary.
Study registration
UNASSIGNED
This study is registered as PROSPERO CRD42019130504.
Funding
UNASSIGNED
This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/135/02) and is published in full in
Cancers of the bowel, ovary or stomach can spread to the lining of the abdomen (‘peritoneal metastases’). Chemotherapy (the use of drugs that aim to kill cancer cells) given by injection or tablets (‘systemic chemotherapy’) is one of the main treatment options. There is uncertainty about whether adding cytoreductive surgery (cytoreductive surgery; an operation to remove the cancer) and ‘hyperthermic intraoperative peritoneal chemotherapy’ (warm chemotherapy delivered into the lining of the abdomen during cytoreductive surgery) are beneficial. We reviewed all the information from medical literature published until 14 April 2022, to answer the above uncertainty. We found the following from eight trials, including about 1000 participants. In people with peritoneal metastases from bowel cancer, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably does not provide any benefits and increases harm compared to cytoreductive surgery + systemic chemotherapy, while cytoreductive surgery + systemic chemotherapy appears to increase survival compared to systemic chemotherapy alone. There is uncertainty about the best treatment for people with peritoneal metastases from stomach cancer. In women with peritoneal metastases from ovarian cancer who require systemic chemotherapy before cytoreductive surgery to shrink the cancer to allow surgery (‘advanced ovarian cancer’), hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably increases survival compared to cytoreductive surgery + systemic chemotherapy. In people who can withstand a major operation and in whom cancer can be removed, cytoreductive surgery + systemic chemotherapy should be offered to people with peritoneal metastases from bowel cancer, while hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy should be offered to women with peritoneal metastases from ‘advanced ovarian cancer’. Uncertainty in treatment continues for gastric cancer. This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/135/02) and is published in full in
Autres résumés
Type: plain-language-summary
(eng)
Cancers of the bowel, ovary or stomach can spread to the lining of the abdomen (‘peritoneal metastases’). Chemotherapy (the use of drugs that aim to kill cancer cells) given by injection or tablets (‘systemic chemotherapy’) is one of the main treatment options. There is uncertainty about whether adding cytoreductive surgery (cytoreductive surgery; an operation to remove the cancer) and ‘hyperthermic intraoperative peritoneal chemotherapy’ (warm chemotherapy delivered into the lining of the abdomen during cytoreductive surgery) are beneficial. We reviewed all the information from medical literature published until 14 April 2022, to answer the above uncertainty. We found the following from eight trials, including about 1000 participants. In people with peritoneal metastases from bowel cancer, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably does not provide any benefits and increases harm compared to cytoreductive surgery + systemic chemotherapy, while cytoreductive surgery + systemic chemotherapy appears to increase survival compared to systemic chemotherapy alone. There is uncertainty about the best treatment for people with peritoneal metastases from stomach cancer. In women with peritoneal metastases from ovarian cancer who require systemic chemotherapy before cytoreductive surgery to shrink the cancer to allow surgery (‘advanced ovarian cancer’), hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably increases survival compared to cytoreductive surgery + systemic chemotherapy. In people who can withstand a major operation and in whom cancer can be removed, cytoreductive surgery + systemic chemotherapy should be offered to people with peritoneal metastases from bowel cancer, while hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy should be offered to women with peritoneal metastases from ‘advanced ovarian cancer’. Uncertainty in treatment continues for gastric cancer. This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/135/02) and is published in full in
Types de publication
Systematic Review
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-139Références
Gurusamy K, Vale CL, Pizzo E, Bhanot R, Davidson BR, Mould T, et al. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness. BMJ Open 2020;10:e039314.
International Agency for Research on Cancer (World Health Organization). Estimated Number of Incident Cases, Both Sexes, All Cancers Excluding Non-melanoma Skin Cancer, Worldwide in 2012; 2017. URL: https://gco.iarc.fr/today/online-analysis-table?mode=cancer&mode_population=continents&population=900&sex=0&cancer=29&type=0&statistic=0&prevalence=0&color_palette=default (accessed 3 December 2017).
Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011;128(11):2717–25.
Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep 2016;6:29765.
Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99(5):699–705.
van Gestel YRBM, Thomassen I, Lemmens VEPP, Pruijt JFM, van Herk-Sukel MPP, Rutten HJT, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 2014;40(8):963–9.
Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol 2016;100:209–22.
Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 2014;134(3):622–8.
Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, Bouvier A-M. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum 2015;58(8):743–52.
Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 2011;22(10):2250–6.
Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, et al. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer 2014;50(10):1747–57.
Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015;22(5):1570–5.
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011;18(6):1575–81.
Verwaal VJ, Van Ruth S, De Bree E, Van Slooten GW, Van Tinteren H, Boot H, Zoetmulder FAN. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21(20):3737–43.
Razenberg LG, van Gestel YR, Creemers GJ, Verwaal VJ, Lemmens VE, de Hingh IH. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. Eur J Surg Oncol 2015;41(4):466–71.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15(9):2426–32.
Elias D, Goere D, Dumont F, Honore C, Dartigues P, Stoclin A, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014;50(2):332–40.
Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, et al. The 30-year experience – a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 2017;79:1–14.
Schaaf L, van der Kuip H, Zopf W, Winter S, Munch M, Murdter TE, et al. A Temperature of 40 °C appears to be a critical threshold for potentiating cytotoxic chemotherapy in vitro and in peritoneal carcinomatosis patients undergoing HIPEC. Ann Surg Oncol 2015;22:S758–65.
Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol 2014;40(12):1605–13.
Huang CQ, Min Y, Wang SY, Yang XJ, Liu Y, Xiong B, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 2017;8(33):55657–83.
Cavaliere D, Cirocchi R, Coccolini F, Fagotti A, Fambrini M, Federici O, et al.; Italian Society of Surgical Oncology (SICO). 1st evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer. Tumori 2017;103(6):525–36.
Baratti D, Scivales A, Balestra MR, Ponzi P, Di Stasi F, Kusamura S, et al. Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 2010;36(5):463–9.
Bonastre J, Chevalier J, Elias D, Classe JM, Ferron G, Guilloit JM, et al. Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer. Value Health 2008;11(3):347–53.
Chua TC, Martin S, Saxena A, Liauw W, Yan TD, Zhao J, et al. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George hospital peritoneal surface malignancy program. Ann Surg 2010;251(2):323–9.
Lee Z, Chia C, Teo M. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy cost-effective for metastatic colorectal cancer? Ann Surg Oncol 2016;23(1 Suppl):S77.
Ludwigs K, Breimer ME, Brorson F, Carlsson G, Daxberg EL, Hjalmarsson Y, et al. Cytoreductive surgery and intraperitoneal chemotherapy (HIPEC or EPIC) in patients with colorectal adenocarcinoma and peritoneal carcinomatosis (Structured abstract). Health Technol Assess Database 2013;4.
Naffouje SA, O’Donoghue C, Salti GI. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: a cost–utility analysis of a hospital’s initial experience and reflections on the health care system. J Surg Oncol 2016;113(5):544–7.
Tentes AAK, Pallas N, Korakianitis O, Mavroudis C, Spiridonidou A, Zorbas G, et al. The cost of cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal malignancy in one Greek institute. J BUON 2012;17(4):776–80.
Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009;16(8):2152–65.
Ceelen WP, Hesse U, de Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 2000;87(8):1006–15.
Chia CS, Seshadri RA, Kepenekian V, Vaudoyer D, Passot G, Glehen O. Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review. Pleura Peritoneum 2016;1(2):67–77.
Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol 2013;107(6):566–73.
Di Vita M, Cappellani A, Piccolo G, Zanghi A, Cavallaro A, Bertola G, et al. The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows. Anticancer Drugs 2015;26(2):123–38.
Eveno C, Pocard M. Randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review. Pleura Peritoneum 2016;1(4):169–82.
He TF, Chen ZR, Xing CG. Cytoreductive surgery combined with intraperitoneal chemotherapy in the treatment of colorectal peritoneal metastasis: a meta-analysis. Int J Clin Exp Med 2016;9(11):20562–70.
Hotouras A, Desai D, Bhan C, Murphy J, Lampe B, Sugarbaker PH. Heated IntraPEritoneal Chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer 2016;26(4):661–70.
Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2015;41(12):1578–89.
Lopez-Lopez V, Cascales-Campos PA, Schneider MA, Gil J, Gil E, Gomez-Hidalgo NR, Parrilla P. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in elderly patients. A systematic literature review. Surg Oncol 2016;25(4):378–84.
Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, et al. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. World J Gastroenterol 2014;20(38):14018–32.
Kireeva GS, Gafton GI, Guseynov KD, Senchik KY, Belyaeva OA, Bespalov VG, et al. HIPEC in patients with primary advanced ovarian cancer: is there a role? A systematic review of short- and long-term outcomes. Surg Oncol 2018;27(2):251–8.
Morano WF, Khalili M, Chi DS, Bowne WB, Esquivel J. Clinical studies in CRS and HIPEC: trials, tribulations, and future directions – a systematic review. J Surg Oncol 2018;117(2):245–59.
Whiting P, Savovic J, Higgins JP, Caldwell DM, Reeves BC, Shea B, et al.; ROBIS group. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol 2016;69:225–34.
Ubago-Pérez R, Matas-Hoces A, Beltrán-Calvo C, Romero-Tabares A. Hyperthermic intraperitoneal chemotherapy. Efficacy and safety in the treatment of ovarian cancer peritoneal carcinomatosis (Structured abstract). Health Technol Assess Database 2013;(4). URL: https://database.inahta.org/article/14082 (accessed 27 February 2023).
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250(2):187–96.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240(2):205–13.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205–16.
Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. URL: www.handbook.cochrane.org (accessed 27 February 2023).
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–88.
Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 1992;21(5):837–41.
Hemming K, Pinkney T, Futaba K, Pennant M, Morton DG, Lilford RJ. A systematic review of systematic reviews and panoramic meta-analysis: staples versus sutures for surgical procedures. PLOS ONE 2013;8(10):e75132.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. introduction–GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64(4):383–94.
National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013; 2013. URL: www.nice.org.uk/process/pmg9/chapter/foreword (accessed 4 June 2018).
Treasury H. The Green Book- Central Government Guidance on Appraisal and Evaluation. HM Treasury; 2022. URL: www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-government/the-green-book-2020(accessed 27 February 2023).
Gurusamy KS, Riviere D, van Laarhoven CJH, Besselink M, Abu-Hilal M, Davidson BR, Morris S. Cost-effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer. PLOS ONE 2017;12(12):e0189631.
ONS. Euro to GBP Exchange. 2022. URL: www.ons.gov.uk/economy/nationalaccounts/balanceofpayments/timeseries/thap/mret (accessed 27 February 2023).
Wilson ECF. A practical guide to value of information analysis. PharmacoEcon 2015;33:105–21.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16(2):231–50.
Antonio CCP, Alida GG, Elena GG, Rocio GS, Jeronimo MG, Luis ARJ, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol 2022;29(4):2617–25.
Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg 2022;157(5):374–83.
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al.; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(2):256–66.
Rau B, Lang H, Konigsrainer A, Gockel I, Rau HG, Seeliger H, et al. 1376O The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial). Ann Oncol 2021;32(Suppl. 5):S1040.
Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 2014;110(3):275–84.
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378(3):230–40.
Anthuber M, Strasmuller A. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal cancer? Chirurg 2021;92(6):573.
Arjona-Sanchez A. Hyperthermic intraperitoneal chemotherapy as adjuvant therapy in locally advanced colon cancer. Tech Coloproctol 2021;25(1):147–8.
Asero S, Caruso M, Vallone N, Luciani AG, Lombardo V, Terranova G, et al. Cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of peritoneal surface malignances: report of a phase II clinical study. In Vivo 2009;23(4):645–7.
Bartlett DL, Ryan DP. The role of HIPEC in patients with advanced colorectal cancer. Clin Adv Hematol Oncol: H&O 2020;18(2):103–5.
Batista TP. Comment on: surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2017;24:630–630.
Batista TP, Carneiro VCG, Tancredi R, Teles ALB, Badiglian L, Leao CS. Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach. Cancer Manag Res 2017;9:869–78.
Behbakht K, Cohn DE, Straughn JM Jr. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. Gynecol Oncol 2018;151(1):4–5.
Cascales Campos PA, Gonzalez-Gil A, Gomez-Ruiz AJ, Gil-Gomez E, Alconchel-Gago F, Navarro-Barrios A, et al. Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies. Hernia 2020;24(2):257–63.
Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, Gonzalez-Gil A, Lopez V, et al. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol 2015;22(3):987–93.
Cashin PH, Mahteme H, Spang N, Syk I, Frodin JE, Torkzad M, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 2016;53:155–62.
ChiCTR-IIR. A Bidirectional Conversion Treatment for Gastric Cancer with Peritoneal Metastasis: A Prospective Phase II Clinical Research. 2017. URL: www.chictr.org.cn/showproj.aspx?proj=20551 (accessed 27 February 2023).
ChiCTR-INR. Cytoreductive Surgery with Intraperitoneal Hyperthermic Perfusion Chemotherapy Clinical Study on Treatment of Peritoneal Carcinoma and Application. 2016. URL: www.chictr.org.cn/showproj.aspx?proj=16497(accessed 27 February 2023).
ChiCTR2100043156. A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Interval Debulking Surgery Combined with Cisplatin and Docetaxel Hyperthermic Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer. 2021. URL: www.chictr.org.cn/showproj.aspx?proj=66616(accessed 27 February 2023).
Chua TC, Liauw W, Robertson G, Chia WKJ, Soo KC, AlObaid A, et al. Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol 2009;114(1):137–9; author reply 139.
Chua TC, Liauw W, Robertson G, Morris DL. Establishing evidence for change in ovarian cancer surgery – proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol Oncol 2009;115(1):166–8.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 2019;381(20):1929–39.
Cui HB, Ge HE, Bai XY, Zhang W, Zhang YY, Wang J, et al. Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp Ther Med 2014;7(5):1083–8.
Dellinger TH, Han ES. Regional therapy for the treatment of ovarian cancer: HIPEC and intraperitoneal chemotherapy. In Fong Y, Gamblin TC, Han ES, Lee B, Zager JS, editors. Cancer Regional Therapy. Cham: Springer International Publishing Ag; 2020. pp. 125–40.
Demuytere J, Carlier C, Willaert W, Tummers P, Denys H, Van Kerschaver O, et al. Debulking and HIPEC for ovarian cancer: effects of perfusion temperature on morbidity and cisplatin pharmacokinetics. Eur J Surg Oncol 2021;47(2):e29.
Elias D, Pocard M, Goere D. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin. Cancer Treat Res 2007;134:303–18.
EUCTR-000138-37-Nl. Treatment of PERItoneal Dissemination in Stomach Cancer Patients with cytOreductive Surgery and Hyperthermic intraPEritoneal Chemotherapy. 2013. URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-000138-37(accessed 27 February 2023).
EUCTR-004058-27-It. Randomized Study Comparing Surgery and Local Chemotherapy Versus Standard Chemotherapy in the Treatment of Colorectal Carcinomatosis. 2013. URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004058-27(accessed 27 February 2023).
EUCTR-009467-59-Be. Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy – HIPEC-Ovarian Carcinoma. 2010. URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009467-59(accessed 27 February 2023).
EUCTR2020-005210-18-SE. EFFIPEC – Efficacy of Heated Chemotherapy Administered into the Abdomen. 2021. URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005210-18(accessed 27 February 2023).
Evrard S, Maziere C, Desolneux G. HIPEC: standard of care or an experimental approach? Lancet Oncol 2012;13(11):e462–3.
Gustave Roussy CCGP. Treatment of a Cancerous Disease of the Peritoneum with Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia. 2003.
Harter P, Reuss A, Sehouli J, Chiva L, du Bois A. Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al. Int J Gynecol Cancer 2017;27(2):246–7.
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al.; DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Eng J Med 2021;385(23):2123–31.
Hilpert F, Harter P, Pujade-Lauraine E, Reuss A, Pfisterer J, Roy-Coquard I, et al. Complete surgical debulking in advanced ovarian carcinoma improves prognosis in any FIGO stage – analysis of 3126 prospectively randomized patients in AGO-OVAR/GINECO Phase 3 Trials. Onkologie 2010;33:107.
Iavazzo C, Spiliotis J. Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer? Arch Gynecol Obstet 2021;303(2):597–8.
Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol 2018;36(19):1922–9.
Jones IHW. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival: An exploratory analysis of a prospectively randomized phase III study of the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group (AGO-OVAR). Obstet Gynecol Surv 2007;62(11):719–20.
Klempner SJ, Ryan DP. HIPEC for colorectal peritoneal metastases. Lancet Oncol 2021;22(2):162–4.
Knodler M, Korfer J, Kunzmann V, Trojan J, Daum S, Schenk M, et al. Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer 2018;119(3):296–302.
Lim SL, Havrilesky LJ, Habib AS, Secord AA. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecol Oncol 2019;153(2):376–80.
NCT. Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer with Peritoneal Metastatis. 2017. URL: https://classic.clinicaltrials.gov/ct2/show/NCT03604614 (accessed 27 February 2023).
NCT. Chemotherapy With or Without Surgery in Treating Patients with Recurrent Ovarian Cancer. 2000. URL: http://clinicaltrials.gov/show/NCT00006356 (accessed 27 February 2023).
NCT. Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis. 2003. URL: https://clinicaltrials.gov/show/NCT00052962 (accessed 27 February 2023).
NCT. Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases. 2016. URL: https://clinicaltrials.gov/show/NCT02758951 (accessed 27 February 2023).
NCT. Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers. 2021. URL: https://ClinicalTrials.gov/show/NCT04795596 (accessed 27 February 2023).
NCT04847063. Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies. 2021. URL: https://clinicaltrials.gov/show/NCT04847063 (accessed 27 February 2023).
Petrillo M, Costantini B, Cianci S, Ronsini C, Cosentino F, Shallayeva E, et al. Comparison of quality of life after secondary cytoreductive surgery (SCS) ± HIPEC in recurrent ovarian cancer. Gynecol Oncol 2015;137:125.
Pocard M, Boige V. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed]. Bull Cancer 2005;92(2):151–4.
Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al.; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Eng J Med 2004;351(24):2489–97.
Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers GJM, Thijs AMJ, et al. Perioperative systemic therapy vs. cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a phase 2 randomized clinical trial. JAMA Surgery 2021;156(8):710–20.
Rovers KP, Bakkers C, Simkens G, Burger JWA, Nienhuijs SW, Creemers GM, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19(1):390.
Rubiales AS, del Valle ML. Survival analysis in a randomized trial of HIPEC in ovarian cancer. Ann Surg Oncol 2017;24:s6–31-s.
Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, et al. Randomized controlled phase III study to evaluate secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer-ago desktop III/ENGOT OV20. Int J Gynecol Cancer 2017;27(Suppl 4):18.
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(4):439–49.
Strohlein MA, Bulian DR, Heiss MM. Clinical efficacy of cytoreductive surgery and hyperthermic chemotherapy in peritoneal carcinomatosis from gastric cancer. Expert Rev Anticancer Ther 2011;11(10):1505–8.
van de Laar R, Kruitwagen R, Zusterzeel PLM, Van Gorp T, Massuger L. Correspondence: premature stop of the SOCceR trial, a multicenter randomized controlled trial on secondary cytoreductive surgery netherlands trial register number: NTR3337. Int J Gynecol Cancer 2017;27(1):2.
Vanderburg MEL, Vanlent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian-cancer. N Eng J Med 1995;332(10):629–34.
Wang P, Zhou ZX. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: trial results of a phase 2, randomized, clinical trial. Ann Surg Oncol 2017;24:s6–23-s.
Wisselink D, Klaver C, Brandt A, Bremers A, Burger J, Van Grevenstein W, et al. Adhesion formation after resection of locally advanced colon cancer within the COLOPEC trial based on standardized reexploration. Colorectal Dis 2019;21(Suppl. 3):61–2.
Yonemura Y, Canbay E, Ishibashi H, Hirano M, Mizumoto A, Takao N, et al. Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of peritoneal metastasis of gastric cancer. In Fong Y, Gamblin TC, Han ES, Lee B, Zager JS, editors. Cancer Regional Therapy. Cham: Springer International Publishing Ag; 2020. pp. 113-24.
Zhang GY, Chen XC, Pan K, Xia LG, Zuo M, Zheng T. Application of hyperthermic intraoperative intraperitoneal chemotherapy in patients with gastric cancer. Zhonghua wei chang wai ke za zhi 2007;10(4):362–4.
Cisplatin uptake in ovarian cancer peritoneal metastases after HIPEC. Pleura Peritoneum 2021;6(3):eA42–eA3.
Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol 2021;39(23):2594–604.
Center MM. HOT: HIPEC in Ovarian Cancer as Initial Treatment. 2014. URL: https://classic.clinicaltrials.gov/ct2/show/NCT02124421 (accessed 27 February 2023).
Center U. Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis. 2017. URL: https://classic.clinicaltrials.gov/ct2/show/NCT03073694 (accessed 27 February 2023).
Center WRAM, Institute NC. Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients with Advanced Limited Peritoneal Dissemination of Colon Cancer. 2010. URL: https://classic.clinicaltrials.gov/ct2/show/NCT01167725 (accessed 27 February 2023).
ChiCTR. A Randomized Controlled Study of Modified Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis of Gastric Cancer. 2020. URL: https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000036567 (accessed 27 February 2023).
Cui SZ, Institute TMUC, Hospital, Hospital CPG, University HM, Southern Medical University C, et al. Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer. 2017. URL: https://classic.clinicaltrials.gov/ct2/show/NCT03179579 (accessed 27 February 2023).
Drks. Prospective Multicenter Phase III Clinical Trial Using Cytoreductive Surgery with Hyperthermic Intraoperative Chemotherapy (HIPEC) after Preoperative Chemotherapy in Patients with Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastreal Junction; 2011. URL: http://www.drks.de/DRKS00003078 (accessed 27 February 2023).
EUCTR. Assessment of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer. HIPOVA-01. 2019. URL: https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-002480-94-FR (accessed 27 February 2023).
Koemans WJ, van der Kaaij RT, Boot H, Buffart T, Veenhof A, Hartemink KJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer 2019;19(1):420.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer 2020;30:888–92.
Liu H, Li G, Su X, Sun Y, Hu J, Huang L, et al. CLASS-05 trial: a randomized controlled phase III trial of cytoreductive surgery 1 hyperthermic intraperitoneal chemotherapy (HIPEC) 1 systemic chemotherapy vesus systemic chemotherapy alone for patients with limited peritoneal carcinomatosis of gastric cancer. Ann Oncol 2017;28(Suppl 5):v263.
NCT. Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment. 2011. URL: https://clinicaltrials.gov/show/NCT01376752 (accessed 27 February 2023).
NCT05250648. Clinical Trial on HIPEC with Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC). 2022. URL: https://clinicaltrials.gov/show/NCT05250648 (accessed 27 February 2023).
Cui SZ, University SYS-S, Third Affiliated Hospital SYSU, Hospital H, University X, University T, et al. Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer. 2018. URL: https://classic.clinicaltrials.gov/ct2/show/NCT03180177 (accessed 27 February 2023).
Diaz-Montes T, Sittig M, Ryu H, Gushchin V, Sardi A. A phase II randomized study: outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by adjuvant chemotherapy as initial treatment of advanced stage (stage III/IV) ovarian, fallopian tube, and primary peritoneal cancer. J Clin Oncol Conf 2016;34(Suppl 15):e17080.
NCT. Efficacy of HIPEC in the Treatment of Advanced-stage Epithelial Ovarian Cancer After Cytoreductive Surgery. 2019. URL: https://classic.clinicaltrials.gov/ct2/show/NCT03373058 (accessed 27 February 2023).
Lambret CO. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI). 2019.
Mexico I. HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy. 2017.
NCT. Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel in Advanced Ovarian Cancer. 2016.
NCT. Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 2018.
NCT. HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC). 2019. URL: https://clinicaltrials.gov/show/NCT04280185 (accessed 27 February 2023).
Salcedo-Hernandez R, Cetina L, Cantu-De-Leon D, Cordoba V, Tiznado R, Isla-Ortiz D, et al. Hyperthermic intraperitoneal chemotherapy in stage IIIC and IV clinical stage ovarian carcinoma during interval laparotomy. Phase II study. Interim analysis of morbility and perioperative mortalityy. Pleura Peritoneum 2018;3(Suppl. 1):sa326–sa7.
Euctr-001715-31-Es. Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients with Peritoneal Carcinomatosis from Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma: Randomized Clinical Trial. 2011. URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001715-31 (accessed 27 February 2023).
Grosso G, Lotti M, Rossetti D, Ansaloni L, Frigerio L. Cytoreduction and HIPEC vs. only cytoreduction surgery after neoajuvant chemotherapy for treatment of ovarian cancer naive patients: a phase III multi center randomized ongoing trial. Int J Gynecol Cancer 2013;23(8 Suppl.1):897.
Hospital Z. Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer. 2017. URL: https://clinicaltrials.gov/study/NCT03371693 (accessed 27 February 2023).
Lyon H. Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer. 2019. URL: https://classic.clinicaltrials.gov/ct2/show/NCT03220932 (accessed 27 February 2023).
Classe JM, Campion L, Meeus P, Quenet F, Leblanc E, Werner R, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) a promising treatment for relapsed intraperitoneal ovarian cancer. Chipor an ongoing phase III, European multicentric randomized trial. Int J Gynecol Cancer 2017;27(Suppl. 4):1467–8.
Du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol 2020;38(15):6000.
Hongbing C, Hospital Z. A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients with HRR Mutation. 2020. URL: https://classic.clinicaltrials.gov/ct2/show/NCT04473339 (accessed 27 February 2023).
NCT. Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer. 2017. URL: https://clinicaltrials.gov/show/NCT03220932 (accessed 27 February 2023).
NTR. LOROCSON study: Late Onset Recurrent Ovarian Cancer: Surgery or Not. 2005. URL: https://trialregister.nl/trial/306 (accessed 27 February 2023).
ChiCTR. A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer After Comprehensive Staging Laparotomy. 2019. URL: https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR1900024452 (accessed 27 February 2023).
El Hajj H, Vanseymortier M, Hudry D, Bogart E, Abdeddaim C, Leblanc E, et al. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery. ESMO Open 2021;6(2):100098.
ChiCTR. A Randomized Controlled Study for Comparing the Efficacy of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) Added in Primary Epithelial Ovarian/fallopian Tube Carcinoma in Primary Exploration and Interval Debulking Surgery (IDS) with Conventional Therapy. 2020. URL: https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000028894 (accessed 27 February 2023).
ChiCTR. A Randomized Controlled Trial for Comparing the Efficacy of Intraperitoneal Hyperthermic Chemotherapy (HIPEC) with Conventional Treatment During Primary Subtractive Surgery (PDS) for Newly Diagnosed Ovarian/fallopian Tube Epithelial Cancer in Stage II–IV. 2020. URL: https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000034192 (accessed 27 February 2023).
National Cancer Center, Korea. HIPEC for Platinum-Resistant Recurrent Ovarian Cancer. 2022. URL: https://ClinicalTrials.gov/show/NCT05316181 (accessed 27 February 2023).
NCT. A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients with HRR Mutation. 2020. URL: https://ClinicalTrials.gov/show/NCT04473339 (accessed 27 February 2023).
Wu MF, Wang LJ, Ye YF, Liu CH, Lu HW, Yao TT, et al. Efficacy of neoadjuvant hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer (the NHIPEC trial): study protocol for a randomised controlled trial. BMJ Open 2021;11(12):e046415.
Anonymous. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. Obstet Gynecol Surv 2019;74(10):592–3.
Cascales Campos PA, Gonzalez Gil A, Gil Gomez E, Gonzalez Sanchez R, Martinez Garcia J, Alonso Romero JL, et al. ASO visual abstract: cytoreductive surgery with or without HIPEC after Neoadjuvant chemotherapy in ovarian cancer: a phase III clinical trial. Ann Surg Oncol 2022;29:2628–9.
Charite University BG, Aid GC. Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer with Peritoneal Carcinomatosis. 2014. URL: https://classic.clinicaltrials.gov/ct2/show/NCT02158988 (accessed 27 February 2023).
Chekman C, Layoune R, Hocine O, Raissi N, Hamida AF, Khodja HA, et al. An open prospective randomized trial comparing primary complete cytoreduction surgery to debulking surgery after chemotherapy in advanced stage (FIGO's IIIC) ovarian carcinoma. Int J Gynecol Cancer 2015;25(9):1316.
Euctr-003466-34-Nl. Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (OVHIPEC-I) – OVHIPEC-I. 2006. URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003466-34 (accessed 27 February 2023).
Euctr-006175-20-Fr. Essai de phase III evaluant la place de la ChimioHyperthermie IntraPeritoneale per operatoire (CHIP) apres resection maximale d’une carcinose peritoneale d’origine colorectale associee a une chimiotherapie systemique – CHIP. 2007. URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006175-20 (accessed 27 February 2023).
Gonzalez Gil A, Gomez Ruiz AJ, Gil Gomez E, Gil Martinez J, Cascales Campos P. Morbidity and mortality after a first cytoreduction with or without HIPEC in ovarian cancer IIIC–IV. Preliminary results of the prospective and randomized clinical trial. Pleura Peritoneum 2018;3(Suppl. 1):sa64.
Gonzalez Gil A, Gomez Ruiz AJ, Gil Gomez E, Gil Martinez J, Cascales Campos P. Quality of life after a first cytoreduction with or without HIPEC in ovarian cancer IIIC–IV. Preliminary results of the prospective and randomized clinical trial. Pleura Peritoneum 2018;3(Suppl. 1):sa343.
Institute NC, Center N. Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial. 2009. URL: https://classic.clinicaltrials.gov/ct2/show/NCT00941655 (accessed 27 February 2023).
Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009;10:121.
Koole S, Bruijs L, Lahaye M, Fabris C, Sikorska K, Schagen Van Leeuwen J, et al. Location of recurrent disease after cytoreduction with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer: results of the phase III ovhipec study. Int J Gynecol Cancer 2018;28(Suppl. 2):611–2.
Koole S, Van Driel W, Kieffer J, Sikorska K, Schagen Van Leeuwen J, Schreuder H, et al. Health-related quality of life after hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer: results of the phase III OVHIPEC study. Ann Oncol 2017;28(Suppl. 5):v627.
Koole S, Van Driel W, Sikorska K, Schagen Van Leeuwen J, Schreuder H, Hermans R, et al. Adverse events after hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer: phase III OVHIPEC study. Int J Gynecol Cancer 2017;27(Suppl. 4):38–9.
Koole SN, Bruijs L, Fabris C, Sikorska K, Engbersen M, Schagen van Leeuwen JH, et al. Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer. Int J Gynecol Cancer 2020;30(12):1928–34.
Koole SN, Kieffer JM, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Eur J Surg Oncol 2021;47(1):101–7.
Koole SN, van Driel WJ, Sonke GS. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on. Cancer 2019;125(Suppl. 24):4587–93.
Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, Kieffer JM, et al. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. J Clin Oncol 2019;37(23):2041–50.
Koole SN, Van Lieshout C, Van Driel WJ, Van Schagen E, Sikorska K, Kieffer JM, et al. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. Obstet Gynecol Surv 2019;74(10):592–3.
Li Y, Yang X, Yang G, Zhou Y, Yonrmura Y. An evaluation of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy on patients with peritoneal carcinomatosis: final results of a phase II prospective and randomized clinical trial. J Clin Oncol Conference: ASCO Annual Meeting 2011;29(15 Suppl. 1):4051.
Li Y, Zhou Y, Xie C, Peng C, Huang C, Yang X, et al. Cytoreductive surgery plus hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis from gastric cancer. Chinese J Clin Oncol 2012;39(22):1734–40.
Lim MC, Chang SJ, Yoo HJ, Nam BH, Bristow R, Park SY. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol Conf 2017;35(15 Suppl. 1):5520.
Murcia F. Cytoreduction With or without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients with Peritoneal Carcinomatosis from Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma. 2012. URL: https://classic.clinicaltrials.gov/ct2/show/NCT02328716 (accessed 27 February 2023).
NCT. Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis. 2007. URL: http://clinicaltrials.gov/show/NCT00454519 (accessed 27 February 2023).
Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. Perioperative outcomes of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal carcinomatosis: PRODIGE 7 randomized trial. Eur J Surg Oncol 2016;42(-9):s107.
Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-Peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol Conf 2018;36(18 Suppl. 1):LBA3503.
Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis. PRODIGE 7. Eur J Surg Oncol 2019;45(2):e17.
Rau B, Loeffler M, Rau HG, Sulkowski U, Kuhlmann J, Weimann A, et al. Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: a randomized phase III study (GASTRIPEC). J Clin Oncol 2015;33(15):TPS4132.
Ubachs J, Koole S, Bruijs L, Lahaye M, Fabris C, Schagen Van Leeuwen J, et al. Loss of skeletal muscle mass during neoadjuvant chemotherapy and the relation to survival in patients with ovarian cancer; a prospective analysis of the ovhipec-1 cohort. Int J Gynecol Cancer 2019;29(Suppl. 4):a532.
Ubachs J, Koole S, Bruijs L, Lahaye M, Fabris C, Van Leeuwen JS, et al. Loss of skeletal muscle mass during neoadjuvant chemotherapy and the relation to survival in patients with ovarian cancer: a prospective analysis of the OVHIPEC-1 cohort. J Cachexia, Sarcopenia and Muscle 2020;11(1):302–3.
Unicancer. Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis from Colorectal Cancer. 2008. URL: https://classic.clinicaltrials.gov/ct2/show/NCT00769405 (accessed 27 February 2023).
Van Driel W, Sikorska K, Van Leeuwen JS, Schreuder H, Hermans R, De Hingh I, et al. A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. J Clin Oncol Conf 2017;35(15 Suppl. 1: 5519).
Van Driel WJ, Koole S, Sikorska K, Schagen Van Leeuwen J, Schreuder HW, Hermans R, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. Int J Gynecol Cancer 2017;27(Suppl. 4):12.
Cashin PH, Mahteme H, Syk I, Frodin JE, Glimelius B, Graf W. Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases. Eur J Surg Oncol 2018;44(7):983–90.
Coleman RL, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim B, et al. A phase III randomized controlled trial of secondary cytoreductive surgery (SCS) followed by platinum-based chemotherapy (PC) platinum-sensitive, recurrent ovarian cancer (PSOC)-surgical parameters. Int J Gynecol Cancer 2018;28(Suppl. 2):52.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. Obstet Gynecol Surv 2020;75(3):165–6.
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer (vol 385, pg 2123, 2021). N Eng J Med 2022;386(7):704.
Lim S, Havrilesky L, Cohn D, Habib A, Secord A. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Int J Gynecol Cancer 2018;28(Suppl. 2):627.
NCT. Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. 2012. URL: http://clinicaltrials.gov/show/NCT01524094 (accessed 27 February 2023).
NCT. Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence. 2012. URL: http://clinicaltrials.gov/show/NCT01539785 (accessed 27 February 2023).
Petrillo M, Costantini B, Cianci S, Ronsini C, Scambia G, Fagotti A. Comparison of quality of life after secondary cytoreductive surgery (SCS) ± hipec in recurrent ovarian cancer. Int J Gynecol Cancer 2014;24(9):63.
Rovers K, Burger J, Wiezer R, Aalbers A, Tuynman J, Radema S, et al. Safety and efficacy of perioperative systemic therapy with cytoreductive surgery and HIPEC versus upfront surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: update of a multicentre, openlabel, parallel-group, phase II–III, randomised superiority study (CAIRO6). Pleura Peritoneum 2018;3(Suppl. 1):sa299–300.
van de Laar R, Zusterzeel PL, Van Gorp T, Buist MR, van Driel WJ, Gaarenstroom KN, et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer 2014;14:22.
Zang R, Zhu J, Shi T, Liu J, Tu D, Yin S, et al. A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2. J Clin Oncol Conf 2020;38(15):6001.
Center MSKC, Clinic M, Florida BHS, HealthCare H, Pittsburgh U, Chicago U. Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. 2013. URL: https://classic.clinicaltrials.gov/ct2/show/NCT01767675 (accessed 27 February 2023).
ChiCTR. A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer After Comprehensive Staging Laparotomy. 2019. URL: https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR1900024452 (accessed 27 February 2023).
ChiCTR. A Randomized Controlled Study of Modified Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis of Gastric Cancer. 2020. URL: https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000036567 (accessed 27 February 2023).
Classe JM, Campion L, Ray coquard I, Leblanc E, Quenet F, Meeus P, et al. Chipor (hyperthermic intraperitoneal chemotherapy for ovarian cancer relapse): ongoing randomized phase III study evaluating hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse. Int J Gynecol Cancer 2013;23(8):862.
Classe JM, Jaffre I, Ioic C, Meeus P, Leblanc E, Houvenaeghel G, et al. CHIPOR (Hyperthermic Intraperitoneal Chemotherapy [HIPEC]) – A promising treatment for relapsed intraperitoneal ovarian cancer. Chipor an ongoing phase III, European multicentric randomized trial. Unicancer-FEDEGYN 02. Strahlenther Onkol 2018;194(5):489.
Classe JM, Meeus P, Ray-Coquard I, Quenet F, Berton-Rigaud D, Leblanc E, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) a promising treatment for relapsed intraperitoneal ovarian cancer. An ongoing phase III, european multicentric randomized trial. Int J Gynecol Cancer 2015;25(9):1319–20.
Du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol Conf 2017;35(15 Suppl. 1):5501.
Euctr-002616-22-It. Efficacy of Intraperitoneal Chemohyperthermia Associated with Cytoreductive Surgery in the Peritoneal Tube Epithelial Neoplasia/Advanced-stage Ovarian. 2012. URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002616-22 (accessed 27 February 202).
Institute TNC. Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 2019. URL: https://classic.clinicaltrials.gov/ct2/show/NCT03772028. (accessed 27 February 2023).
The Netherlands Cancer Institute. Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 2020. URL: https://ClinicalTrials.gov/show/NCT03772028 (accessed 27 February 2023).
Institute TNC, Center EM, Hospital SA, Groningen UMC, Eindhoven CZ. Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer with Peritoneal Dissemination. 2017. URL: https://classic.clinicaltrials.gov/ct2/show/NCT03348150 (accessed 27 February 2023).
NCT. HIPEC in the Treatment of Stage IIc–IV Epithelial Ovarian Cancer after CRS (HIPECOC). 2020. URL: https://ClinicalTrials.gov/show/NCT04280185 (accessed 27 February 2023).
NCT05246020. Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial). 2022. URL: https://clinicaltrials.gov/show/NCT05246020 (accessed 27 February 2023).
Van Stein RM, Koole SN, Sikorska K, Barton DP, Perrin L, Brennan D, et al. Primary cytoreductive surgery with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: the OVHIPEC-2 trial in progress. J Clin Oncol Conf 2020;38(15):TPS6100.
Zivanovic O, Chi D, Zhou Q, Iasonos A, Makker V, Grisham RN, et al. A randomized phase II trial of secondary cytoreductive surgery (SCS) ± carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with recurrent platinumsensitive ovarian cancer (EOC). J Clin Oncol Conf 2020;38(15 Suppl.1):6016.
Leimkuhler M, Hentzen J, Hemmer PHJ, Been LB, van Ginkel RJ, Kruijff S, et al. Systematic review of factors affecting quality of life after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2020;27(10):3973–83.
Kim SH, Jo MW, Kim HJ, Ahn JH. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes 2012;10:151.
Malcolm FL, Adiamah A, Banerjea A, Whitehead D, Gupta A, West J, Humes DJ; Nottingham Colorectal Service. Long-term health-related quality of life following colorectal cancer surgery: patient-reported outcomes in a remote follow-up population. Colorectal Dis 2021;23(1):213–25.
Flyum IR, Mahic S, Grov EK, Joranger P. Health-related quality of life in patients with colorectal cancer in the palliative phase: a systematic review and meta-analysis. BMC Palliat Care 2021;20(1):144.
van der Wielen N, Daams F, Rosati R, Parise P, Weitz J, Reissfelder C, et al. Health related quality of life following open versus minimally invasive total gastrectomy for cancer: results from a randomized clinical trial. Eur J Surg Oncol 2022;48(3):553–60.
Carter GC, King DT, Hess LM, Mitchell SA, Taipale KL, Kiiskinen U, et al. Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review. J Med Econ 2015;18(11):954–66.
Cashin P, Sugarbaker PH. Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7. J Gastrointest Oncol 2021;12(Suppl 1):S120–8.
Simkens GA, Wintjens A, Rovers KP, Nienhuijs SW, de Hingh IH. Effective strategies to predict survival of colorectal peritoneal metastases patients eligible for cytoreductive surgery and HIPEC. Cancer Manag Res 2021;13:5239–49.
de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Doukas M, Verhoef C, Burger JWA. The accuracy of the surgical Peritoneal Cancer Index in patients with peritoneal metastases of colorectal cancer. Dig Surg 2021;38(3):205–11.
Nickerson RS. Confirmation bias: a ubiquitous phenomenon in many guises. Rev Gen Psychol 1998;2(2):175–220.
Cancer Research UK. Bowel Cancer Survival Statistics. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival (accessed 27 February 2023).
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17(24):2815–34.
Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al.; ESMO Guidelines Committee. Electronic address:clinicalguidelines@esmo.org. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34(1):10–32.
Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 2022;41:678–700.
Associazione Italiana di Oncologia Medica. Tumori Peritoneali Primitivi Esecondari. URL: https://snlg.iss.it/wp-content/uploads/2022/01/LG-457-AIOM_Peritoneo.pdf (accessed 27 February 2023).
Arjona-Sánchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Concepción Martín V, et al. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer 2018;18(1):183.
Flood MP, Kong JCH, Wilson K, Mohan H, Waters PS, McCormick JJ, et al. The Impact of neoadjuvant chemotherapy on the surgical management of colorectal peritoneal metastases: a systematic review and meta-analysis. Ann Surg Oncol 2022;29(11):6619–31.
Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. Ann Oncol 2022;33:878–92.
Drummond M. Methods for the Economic Evaluation of Health Care Programmes. 4th edn. Oxford, UK; New York, NY, USA: Oxford University Press; 2015. p. xiii, 445.
Foundation Trust Network. Operating Theatres – Maximising a Valuable Resource. 2022. URL: https://nhsproviders.org/media/1128/operating-theatres-final.pdf (accessed 27 February 2023).
Office for National Statistics. Consumer Price Inflation Tables. 2022. URL: www.ons.gov.uk/economy/inflationandpriceindices/datasets/consumerpriceinflation (accessed 27 February 2023).
NHS England. NHS Tariffs November. 2022. URL: www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/ (accessed 27 February 2023).
Joint Formulary Committee. British National Formulary 83: London: BMJ Group and Pharmaceutical Press; 2022.
Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLOS ONE 2010;5(1):e8933.
NHS Reference Costs. URL: www.england.nhs.uk/publication/2020-21-national-cost-collection-data-publication/ (accessed February 2023).
Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes – a systematic review. Int J Cancer 2012;130(12):2845–56.